RxDoctor Payments Data

Susan Rife, DO

Family Medicine · Orland Park, ILNPI 1720067234

Payments from drug & device makers

$14,950in general payments, 2019–2025

Across 531 payments — averaging $28.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$4K
  • AstraZeneca$2K
  • Novo Nordisk$2K
  • AbbVie$1K
  • Lilly USA, LLC$971
  • Amarin Pharma, Inc.$669
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$14,932100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,950 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$393,307
Medicare patients
450
Services billed
5,645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide71$76,773
WegovySemaglutide34$50,308
OzempicSemaglutide46$47,905
TrulicityDulaglutide40$44,498
EliquisApixaban36$27,290
AbrysvoRsv Vacc, Pref A And Pref B/Pf49$15,668
JardianceEmpagliflozin17$15,610
XareltoRivaroxaban14$11,647
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,092
ShingrixVaricella-Zoster Ge/As01b/Pf35$7,817
MyrbetriqMirabegron14$6,153
Levothyroxine Sodium365$4,494
Atorvastatin Calcium392$3,715
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$3,554
Fentanyl26$2,912

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$971$121,271111 claims
Novo NordiskWegovy, Ozempic$1,921$98,21380 claims
PfizerEliquis, Abrysvo$342$42,95885 claims
Boehringer IngelheimJardiance$282$15,61017 claims
Johnson & JohnsonXarelto$4,275$11,64714 claims
AstraZenecaBreztri Aerosphere$2,055$10,09216 claims
GSKShingrix$376$7,81735 claims
AbbVieSynthroid$1,184$1,39620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Orland Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →